PolarisQB

PolarisQB is a company that specializes in Quantum-Aided Drug Design (QuADD), offering a Software-as-a-Service (SaaS) platform aimed at enhancing pharmaceutical drug discovery. Their platform utilizes quantum annealing computers to streamline the drug discovery process, allowing researchers to generate approximately 10^30 structures from a 3D protein structure with a bound ligand.

QuADD is designed to create screening libraries of 2,000 to 5,000 novel and synthesizable compounds. These compounds are tailored to fit well into binding pockets, retain essential interactions, and ensure chemical diversity. The platform's Best-In-Class mode focuses on generating molecules with optimal drug-like properties, making it particularly useful for projects involving challenging proteins that may not have extensive published data. By providing high-quality screening libraries more quickly than traditional methods, QuADD helps reduce risks in preclinical stages and accelerates the path to clinical programs.